There are currently different possibilities for the registration / authorisation of biocidal products:
Upcoming deadlines for 2021:
Didecyldimethylammonium chloride (DDAC) and Alkyl (C12-16) dimethylbenzyl ammonium chloride (ADBAC): The Biocidal Products Committee (BPC) intends to decide on approval or non-approval of DDAC and ADBAC for PT1 and PT2 in December 2021.
Chrysanthemum cinerariaefolium, extracts: The Biocidal Products Committee (BPC) intends to decide on approval or non-approval of two Chrysanthemum cinerariaefolium extracts for use in PT18 and PT19 in December 2021.
Propiconazole: The Biocidal Products Committee (BPC) intends to decide about renewal of propiconazole, PT8, in March 2022.
News in 2021:
ECHA’s Biocidal Products Committee (BPC) concluded in its opinion that d-allethrin
should not be approved for product-type 18 (insecticides, acaricides
and products to control other arthropods). The committee considered that
the toxicological test data presented in the dossier submitted does not
sufficiently match the profile of d-allethrin currently placed on the
market. The committee also identified unacceptable risks to human health
and the environment from the use of the substance.
RAC Committee to decide harmonized classification of silver
Under the BPR, classification and labeling according to the CLP Regulation (EU No. 1272/2008) has a direct influence on the evaluation of biocidal active substances. If active substances fulfill the exclusion criteria according to Art. 5(1) BPR, they are not approvable.
One year ago, the Swedish competent authority KEMI submitted a CLH proposal for silver. With the proposed classification "toxic for reproduction category 1B" (inter alia), silver would meet the above exclusion criteria.
Therefore, if the classifications proposed by KEMI were to be adopted by the Committee for Risk Assessment (RAC), this would be equivalent to a ban for biocidal applications.
Such a classification would also have immediate complex regulatory consequences for other uses of silver, due to other regulations (REACH, SCIP, MDR, IVDR, etc.).
RAC will discuss the CLH proposal during one of its upcoming meetings.
The legal deadline for opinion adoption is 16. March 2022.